Manufacturers of a chronic pain patch are changing dosing instructions in order to try to circumvent the potential for overdose risks.
In February 2008, 25 mcg/hr Duragesic patches sold by Janssen-Ortho Inc. and 25 mcg/hr Ran Fentanyl Transdermal System Patches sold by Ranbaxy Laboratories were voluntarily recalled for overdose risks. These pain patches treat persistent to severe chronic pain for people who are getting no pain relief in other products.
The new dose guidelines are to convert adult patients from their current oral or injection therapy to the fentanyl transdermal patch.
People using the pain patches without any problems should not stop or decrease their dosage without talking to their doctors.
Subscribe to:
Post Comments (Atom)
Posts
0 comments:
Post a Comment